ArticleNanoscale2022
Gold nanocluster adjuvant enables the eradication of persister cells by antibiotics and abolishes the emergence of resistance.
Article in Nanoscale, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- A rational approach to discovering new persister control agents.Antimicrobial agents and chemotherapy · 2025Article
- Management Strategies for Chronic Suppurative Otitis Media and Why They Fail.Journal of the Association for Research in Otolaryngology : JARO · 2025Review
- Mechanistic insights and therapeutic innovations in engineered nanomaterial-driven disruption of biofilm dynamics.RSC advances · 2025Review
- Gold Nanoparticle Adsorption and Uptake are Directed by Particle Capping Agent.Small science · 2025Article
- Deciphering meropenem persistence inAntimicrobial agents and chemotherapy · 2025Article
- Antibacterial nanoagents: an emerging arsenal against bacterial persisters.Frontiers in microbiology · 2025Review
- Mini review: Persister cell control strategies.Frontiers in pharmacology · 2025Review
- Molecular mechanism and application of emerging technologies in study of bacterial persisters.BMC microbiology · 2024Review
- Overcoming microbial resuscitation using stable ultrafine gold nanosystems.Nanoscale advances · 2024Article
- Bacterial Persister Cells and Development of Antibiotic Resistance in Chronic Infections: An Update.British journal of biomedical science · 2024Review
- Pheromone cCF10 inhibits the antibiotic persistence ofFrontiers in microbiology · 2024Article
- Eradication of Bacterial Persister Cells By Leveraging Their Low Metabolic Activity Using Adenosine Triphosphate Coated Gold Nanoclusters.Nano today · 2023Article
- Overcoming barriers: a review on innovations in drug delivery to the middle and inner ear.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Persister cells are responsible for relapses of infections common in cystic fibrosis and chronic suppurative otitis media (CSOM). Yet, there are no Food and Drug Administration (FDA) approved antibiotics to eradicate persister cells. Frustratingly, the global preclinical bacterial pipeline does not contain antibacterial agents targeting persister cells. Therefore, we report a nontraditional antimicrobial chemotherapy strategy based on gold nanoclusters adjuvant to eradicate persister cells by existing antibiotics belonging to that different class. Compared to killing with antibiotics alone, combining antibiotics and AuNC@CPP sterilizes persister cells and biofilms. Enhanced killing of up to 4 orders of magnitude in a validated mouse model of CSOM with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.